WhichPeps

GHRP-2

Growth-hormone secretagogue hexapeptide

GH-axis physiology
Generic peptide vial illustrationGHRP-2
Evidence levelLimited human
Human evidenceLimited
Regulatory statusNot FDA-approved

What you need to know in 20 seconds

What is it?Growth-hormone secretagogue hexapeptide
Research focusGH-axis physiology
Human evidenceSmall human physiology studies show GH release, increased food intake and activation of ACTH/prolactin pathways.
Regulatory statusNot FDA-approved; FDA highlights compounding safety uncertainty.
Main limitationsMeaningful muscle gain, fat loss, recovery, longevity or long-term safety.
SafetyFDA cites immunogenicity concerns and serious adverse-event reports in some clinical contexts; causality may be uncertain.
i
Small human physiology studies show GH release, increased food intake and activation of ACTH/prolactin pathways.

What the evidence actually supports

  • ✓This is an important counterpoint to any positioning of GHRP-2 as a straightforward fat-loss compound.
  • ✓Add to safety/unknowns and comparisons.

What is not established / key limitations

  • ×No evidence here for weight-loss efficacy.
  • ×No clinical benefit follows from transient endocrine changes.

Selected study & evidence records

GHRP-2 increases food intake in healthy men

2005 · Randomized placebo-controlled crossover physiology study · n=7

Participants consumed about 35.9% more food during GHRP-2 exposure than saline.

Study detail → Primary source ↗

GHRP-2 endocrine response in healthy men

2009 · Small controlled physiology study · n=10

GHRP-2 increased GH, ACTH and prolactin; vasopressin was not stimulated.

Study detail → Primary source ↗

Safety and unknowns

FDA cites immunogenicity concerns and serious adverse-event reports in some clinical contexts; causality may be uncertain.

Can stimulate appetite and GH; endocrine effects can extend beyond a simple GH-only narrative. Long-term efficacy and safety for physique use are not established.

Technical details

Mechanism / biologyActivates the ghrelin/GHS receptor to stimulate pituitary GH release.
Route / formulation boundaryAcute hormone release does not prove body-composition or performance benefit.
Identity / data-quality noteUse the canonical compound identity and studied formulation when interpreting evidence.
Dosing evidence statusVerified dosing evidence added. Published human challenge-study regimen. See dosing_evidence records for route, regimen, population, duration and source.
Identifiers & alternate namesGHRP2 · GHRP 2

Evidence rule: WhichPeps keeps human, animal, laboratory, regulatory and product/formulation evidence distinct. Common names help people find the page; they do not change the underlying scientific identity.